These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside. Lambe CU; Resetar A; Spector T; Koszalka GW; Nelson DJ Antimicrob Agents Chemother; 1992 Feb; 36(2):353-60. PubMed ID: 1318679 [TBL] [Abstract][Full Text] [Related]
3. Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination. Champney KJ; Lauter CB; Bailey EJ; Lerner AM J Clin Invest; 1978 Dec; 62(6):1142-53. PubMed ID: 219024 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of vidarabine in the treatment of polyarteritis nodosa. Fauvelle F; Léon A; Nicolas P; Tod M; Guillevin L; Petitjean O Fundam Clin Pharmacol; 1992; 6(1):11-5. PubMed ID: 1348236 [TBL] [Abstract][Full Text] [Related]
5. Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. Fauvelle F; Nicolas P; Leon A; Tod M; Perret G; Petitjean O; Guillevin L Biopharm Drug Dispos; 1991; 12(6):411-24. PubMed ID: 1681957 [TBL] [Abstract][Full Text] [Related]
6. High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine. McCann WP; Hall LM; Siler W; Barton N; Whitley RJ Antimicrob Agents Chemother; 1985 Aug; 28(2):265-73. PubMed ID: 2423028 [TBL] [Abstract][Full Text] [Related]
8. Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate. Preiksaitis JK; Lank B; Ng PK; Brox L; LePage GA; Tyrrell DL J Infect Dis; 1981 Oct; 144(4):358-64. PubMed ID: 6169773 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. Shope TC; Kauffman RE; Bowman D; Marcus EL J Infect Dis; 1983 Oct; 148(4):721-5. PubMed ID: 6313815 [TBL] [Abstract][Full Text] [Related]
10. Effect of an adenosine deaminase inhibitor on the uptake and metabolism of arabinosyl adenine (Vidarabine) by intact human erythrocytes. Chang T; Glazko AJ Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):127-40. PubMed ID: 935646 [TBL] [Abstract][Full Text] [Related]
11. 9-beta-D-arabinofuranosyladenine 5'-phosphate metabolism and excretion in humans. LePage GA; Naik SR; Katakkar SB; Khaliq A Cancer Res; 1975 Nov; 35(11 Pt 1):3036-40. PubMed ID: 1182697 [TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of varicella zoster virus to adenine arabinoside and hypoxanthine arabinoside. Bryson YJ; Connor JD Antimicrob Agents Chemother; 1976 Mar; 9(3):540-3. PubMed ID: 176937 [TBL] [Abstract][Full Text] [Related]
13. Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Aronoff GR; Szwed JJ; Nelson RL; Marcus EL; Kleit SA Antimicrob Agents Chemother; 1980 Jul; 18(1):212-4. PubMed ID: 7416747 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of paracetamol, diclofenac and vidarabine during plasma exchange. Fauvelle F; Leon A; Niakate MT; Petitjean O; Guillevin L Int J Artif Organs; 1988 May; 11(3):195-200. PubMed ID: 2900216 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory and lethal concentrations of 9-beta-D-arabinofuranosyladenine and its hypoxanthine-derivative versus herpes simplex virus, type 1. Williams BB; Bailey EJ; Lerner AM J Lab Clin Med; 1977 Apr; 89(4):687-91. PubMed ID: 191546 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Malspeis L; Grever MR; Staubus AE; Young D Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279 [TBL] [Abstract][Full Text] [Related]
17. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3. Suling WJ; Rice LS; Shannon WM Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695 [No Abstract] [Full Text] [Related]
18. Reversed-phase high-performance liquid chromatographic method to determine vidarabine and hypoxanthine arabinoside in biological fluids. Bowman DB; Kauffman RE J Chromatogr; 1982 May; 229(2):487-91. PubMed ID: 7096487 [No Abstract] [Full Text] [Related]
19. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of bethanidine in hypertensive patients. Shen D; Gibaldi M; Israili A; Bellward G; Cunningham R; Throne M; Dayton P; McNay J Clin Pharmacol Ther; 1975 Mar; 17(3):363-73. PubMed ID: 1120401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]